1 May 2023 - The May 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The May issue of the Schedule includes a few major new/revised listings:

• Abiraterone acetate and methylprednisolone (Yonsa MPRED) - new combination product
• Asciminib hydrochloride (Scemblix) - new medicine
• Elexacaftor with tezacaftor and ivacaftor and ivacaftor (Trikafta) - new indication
  
• Lenvatinib mesylate (Lenvima) - new indication
• Ozanimod hydrochloride (Zeposia) - new indication
• Pembrolizumab (Keytruda) - new indication
• Upadacitinib monohydrate (Rinvoq) - new indication
• Ustekinumab (Stelara) - new indication
• Vosoritide (Voxzogo) - new medicine

Read Summary of PBS changes